WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix,
Inc. (the "Company") (Nasdaq: NURO), an innovative health care
company that develops wearable medical technology and point-of-care
tests to help patients and physicians manage chronic pain, nerve
diseases, and sleep disturbances, today said it plans to issue its 2014
first quarter financial results before the opening of the market on
April 24, 2014. The Company will host a conference call at 8:00 a.m.,
Eastern Time on April 24, 2014 to discuss its financial results as well
as business developments affecting the Company.
The conference call may be accessed in the United States by dialing
866-515-2913 and using the confirmation code 40938233. Internationally,
the conference call may be accessed by dialing 617-399-5127 and using
the same confirmation code. The earnings press release and accompanying
condensed financial statements will be accessible from the Company's
website at www.NeuroMetrix.com
under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours
after the call by dialing 888-286-8010, domestically and 617-801-6888,
internationally. The confirmation code to access the replay is 46916035.
The replay will be available for two weeks after the conference call.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care diagnostics that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The company markets
the SENSUS™ Pain Management System for treating chronic pain,
focusing on physicians managing patients with painful diabetic
neuropathy and other forms of chronic pain such as fibromyalgia,
shingles (post herpetic neuralgia), and conditions involving both
chronic pain and disturbed sleep such as restless leg syndrome. The
company also markets the DPNCheck® device, which is a rapid,
accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
